A double-blind Phase I study to investigate safety, tolerability, andpharmacokinetics of single and repeated escalating doses of the NK1 receptor antagonistEU-C-001 given as intravenous infusions and as oraladministrations in healthy male subjects

Trial Profile

A double-blind Phase I study to investigate safety, tolerability, andpharmacokinetics of single and repeated escalating doses of the NK1 receptor antagonistEU-C-001 given as intravenous infusions and as oraladministrations in healthy male subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Mar 2017

At a glance

  • Drugs EU-C 001 (Primary) ; EU-C 001 (Primary)
  • Indications Brain injuries
  • Focus Adverse reactions
  • Sponsors PresSura Neuro Pharmaceuticals
  • Most Recent Events

    • 20 Mar 2017 Status changed from not yet recruiting to recruiting.
    • 17 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top